Novartis, Ono, Pfizer, Sanofi and Takeda, Grant/research support from: Asahi Kasei, Abbvie, Lilly, Novartis, Roche, Pfizer, MSD.

Disclosure of Interests: Mariagrazia Lorenzin: None declared, Augusta Ortolan: None declared, Maria Sole Chimenti: None declared, Antonio Marchesoni Grant/research support from: AM has received honoraria and speaker fees from Abbvie, Pfizer, MSD.

DOI: 10.1136/annrheumdis-2021-eular.2079

POSO097

EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN NAÏVE OR TNF-INHIBITORS FAILURE AXIAL Spondylarthropathies patients in real life: A 24-MONTHS PROSPECTIVE MULTICENTRIC STUDY

M. Lorenzin1, A. Ortolan1, M. S. Chimenti2, A. Marchesoni3, E. Lubrano4,

Consecutive patients with active axSpA (diagnosis according Assessment of SpondyloArthritis International Society ASAS criteria), who started SEC treatment, were evaluated prospectively.Data on disease characteristics, previous/ongoing treatments and imaging were collected. Disease-activity/function/clinical scores and biochemical values were recorded at baseline (T0), at 6 (T6), 12 (T12), and 24 (T24) months. Effectiveness was evaluated over-time with descriptive statistics. Anova (Kruskal Wallis) and generalized linear models were used to compare variables over-time. Infections, adverse events were collected.

Results: One-hundred-seven patients [49.53% men; median age 49.8years; median treatment duration 18.5years] were enrolled;53(49.53%) had HLA-B27, 47.66% were r-axSpA and 52.34% n-axSpA. Signs of sacroilitis were present on MRI in 97 (90.65%) and X-rays in 51 (47.66%). SEC was prescribed as first line treatment in 32 (29.9%) patients and as second or more line biological treatment in 97 (90.65%) and X-rays in 51 (47.66%). SEC was prescribed as first line biological treatment of 8 Italian Rheumatologic centers for 24-months.

The treatment during the follow-up mainly because of primary (7) or secondary loss of efficacy (9). Only 7 patients suspended SEC because of adverse events. A low number of episodes of mild infections (19) occurred;SEC was instead permanently discontinued in 4 cases for oral refractory mucositis (2);recurrent aphthosis (1); recurrent broncopneumoniae (1). The retention rate at T24 was good in the whole population (73%). Survival curves for Group A and B were similar (log-rank test=0.81;p=0.69).

Conclusion: In a real-life clinical setting, SEC was safe and effective in axSpA, as shown by a significant decrease of BASDAI and ASDAS over a 24-months follow-up.

Baseline characteristics of 107 axSpA patients treated with secukinumab in the period January 2017- December 2020.

Disclosure of Interests: Mariagrazia Lorenzin: None declared, Augusta Ortolan: None declared, Maria Sole Chimenti: None declared, Antonio Marchesoni Grant/research support from: AM has received honoraria and speaker fees from Abbvie, Pfizer, MSD.

UCB, Novartis, Janus-Elly, Ennio Lubrano, None declared, Leonardo Santo Stefano, Momenta: Speaker from: Janus-Elly, Novartis, Pfizer, UCB, Momenta, Angulo, Semerano: None declared, Carlo Salvator: None declared, Nicola Girolimetto: None declared, Emanuela Praino: None declared, Giulia Lavinia Fonti: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2121

POSO028

NETAKIAMIN Efficacy in ANTI-TNF-NAIVE and ANTI-TNF-INHIBITED EXPERIENCED PATIENTS WITH Active ANKYLOSING SPONDYLITIS RESULTS OF SUBANALYSIS OF PHASE 3 ASTERI A

S. Erdes1, V. Mazurov2, T. Dubinina3, I. Gaydukova4-6, A. Kuznder2, N. Soroka2, A. Eremeeva7; 1Nasonova Research Institute of Rheumatology, Laboratory of Spondyloarthopathies, Moscow, Russian Federation; 2Mechnikov North-Western State Medical University, Department of Rheumatology and Therapy; 3Moscow, Russian Federation; 4St. Petersburg, Russia; 5University of Padova, Rheumatology Unit, Department of Medicine

Disclosure of Interests: Mariagrazia Lorenzin: None declared, Augusta Ortolan: None declared, Maria Sole Chimenti: None declared, Antonio Marchesoni Grant/research support from: AM has received honoraria and speaker fees from Abbvie, Pfizer, MSD.

UCB, Novartis, Janus-Elly, Ennio Lubrano: None declared, Leonardo Santo Stefano: Momenta: Speaker from: Janus-Elly, Novartis, Pfizer, UCB, Momenta, Angulo, Semerano: None declared, Carlo Salvator: None declared, Nicola Girolimetto: None declared, Emanuela Praino: None declared, Giulia Lavinia Fonti: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2121

Downloaded from http://ard.bmj.com/ on May 10, 2022 by guest. Protected by copyright.